ACS And GI Bleeding PPI Indication Tool
Gastrointestinal bleeding risk assessment
Select the patient's antithrombotic treatment and gastrointestinal risk factors.
PPI recommendation
| Assessment item | Selected response |
|---|
How to interpret this assessment
For patients with acute coronary syndrome (ACS), the 2025 ACC/AHA ACS guideline recommends a proton pump inhibitor (PPI) alongside dual antiplatelet therapy, oral anticoagulant therapy, or both when gastrointestinal bleeding risk is high. This tool provides a structured prompt for assessing selected risk factors; it is not a validated bleeding-risk score.
Risk-factor approach used in this tool
- Major factors: previous gastrointestinal ulcer or haemorrhage, chronic NSAID or systemic corticosteroid use, and oral anticoagulant therapy.
- Additional factors: age 65 years or older, dyspepsia, GERD, Helicobacter pylori infection, and chronic alcohol use. The 2023 ESC guideline lists two or more of these additional factors as a reason to consider PPI protection in patients receiving DAPT.
- Interpretation: any major factor or at least two additional factors flags increased gastrointestinal risk for clinical review. The result does not replace assessment of the full clinical context.
Important limitations
The risk-factor grouping displayed here is a practical aid based on guideline descriptions, not a prospectively validated prediction model. The 2025 ACC/AHA recommendation is framed around high gastrointestinal bleeding risk and does not endorse this tool's questions as a formal score. Consider other clinical factors, active bleeding, drug interactions, treatment duration, and local guidance.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.